

ABSTRACT

INHIBITING EXPRESSION OF ATHEROGENIC MICRORNA-24 AND MICRORNA-125 AND INDUCING EXPRESSION OF ANTI-ATHEROGENIC MICRORNA-126, MICRORNA-222 AND MICRORNA-LET7B

Claimed is a method for inhibiting expression of atherogenic microRNA-24 and microRNA-125 and inducing expression of anti-atherogenic microRNA-126, microRNA-222 and microRNA-let7b in human blood plasma. The invention relates to the field of clinical medicine, and more particularly to the possibility of influencing the expression profile of specific microRNA in human blood plasma by ingestion of angelica extract, allowing the future use of angelica extract as an agent for protecting against the effect of specific epigenetic atherogenic factors in human blood plasma. The technical result of the claimed method is that of making it possible to influence the expression profile of specific microRNA (microRNA-24, -125, -126, -222, -let7b) in blood plasma by inhibiting the expression of atherogenic microRNA (microRNA-24, -125) and inducing the expression of anti-atherogenic microRNA (microRNA-126, -222, -let7b) by ingestion of angelica extract. This technical result is achieved in that the claimed method involves successively carrying out the following steps: 1) obtaining angelica extract; 2) ingesting the obtained angelica extract in a daily amount of 5 drops per 10 kg of body weight for a period of 4 weeks.

(No figure)